Zevalin plus BEAM beats BEAM alone in ASCT
Spectrum Pharmaceuticals is reporting results from a randomized study pitting the company's oncology product Zevalin plus high-dose BEAM chemotherapy (called Z-BEAM) against BEAM chemotherapy alone.
The study was designed to evaluate both the safety and the efficacy of Z-BEAM and an autologous stem cell transplantation in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.
Z-BEAM outperformed BEAM in terms of two-year survival rate, 91% to just 62%.
These results are encouraging, and Spectrum believes that on confirmation of these results, they can receive FDA approval of Zevalin for this indication.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
